Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2017-09-28 Annual Report
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Annual Report to Shareholders 49 pages 1.7MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT' and covers the financial year ended 30 June 2017. It includes detailed sections such as Directors' Report, Auditor's Independence Statement, Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, Statement of Cash Flows, Notes to Financial Statements, Directors' Declaration, Independent Auditor's Report to Members, Corporate Governance, and Shareholders Information. The content includes comprehensive financial data, management discussion, corporate directory, and auditor's report, which are typical components of a full annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2017
2017-09-28 English
Appendix 4G 11 pages 227.6KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. It includes detailed disclosures about the company's adherence to the ASX Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2017. The document is a corporate governance statement or key to disclosures, which is typically part of governance information rather than a full annual report or other financial filings. The content focuses on governance practices, board structure, and compliance with governance recommendations, not on financial results or audit opinions. Therefore, the document fits best under the category 'Governance Information' (CGR). The document length (15,000 characters) and detailed governance content support this classification with high confidence.
2017-09-28 English
Appendix 4E Preliminary Financial Results 12 pages 832.1KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary final Report' and references the year ended 30 June 2017. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are typically preliminary annual financial reports. The document contains detailed financial statements including income statement, statement of financial position, cash flow statement, and management discussion and analysis. It also includes operational review, intellectual property updates, and subsequent events. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document is a full annual report equivalent, specifically a preliminary final report, which aligns with the Annual Report category (10-K) in the classification scheme. FY 2017
2017-08-30 English
Publication of BARD1 Lung Cancer Test 2 pages 232.1KB
Regulatory Filings Classification · 95% confidence The document is an announcement from BARD1 Life Sciences Limited about the publication of a scientific paper in the journal PLOS ONE regarding their BARD1 Lung Cancer Test. It summarizes the study's purpose, methods, results, and conclusions, and provides context about the company's focus and the significance of the publication. The document does not contain financial data, regulatory filings, or detailed financial reports. It is primarily a press release announcing the publication of a research paper, not a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. Given the nature of the content, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2017-08-07 English
Australian Patent Issued 2 pages 462.3KB
Regulatory Filings Classification · 95% confidence The document is an announcement from BARD1 Life Sciences Limited regarding the issuance of an Australian patent related to their lung cancer test technology. It details the patent family, patent numbers, jurisdictions, and the company's intellectual property portfolio. The content is focused on intellectual property updates and patent status rather than financial performance, management changes, or regulatory filings. It is a typical corporate announcement about patent issuance and intellectual property status, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2017-08-06 English
Appendix 3B 12 pages 671.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number of shares issued, issue price, purpose of the issue, and compliance with ASX rules. It includes sections on quotation of securities, calculation of placement capacity under ASX rules, and warranties to ASX. The document is a formal announcement related to the issuance of new shares and application for quotation on the ASX, consistent with regulatory filings for capital raising activities. It does not contain financial statements or management discussion, nor is it a report or transcript. The document fits the category of Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through new share issuance.
2017-08-06 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.